TY - JOUR
T1 - Metabolism-based drug design and drug targeting
AU - Prokai, Laszlo
AU - Prokai-Tatrai, Katalin
PY - 1999/11/1
Y1 - 1999/11/1
N2 - Even at the early stages of drug discovery and structure-based drug design, the pharmacokinetic, pharmacodynamic and toxicological consequences of drug metabolism cannot be ignored. Drug metabolism is also of interest to medicinal chemists in the design of drugs with controlled, predictable deactivation after achieving the therapeutic objective in prodrug design and in chemical-enzymatic drug targeting. In this review, the authors provide an overview of concepts that can be utilized from drug discovery to pharmaceutical development to overcome problems associated with drug metabolism, or that may be used to take advantage of 'designed-in' metabolic activation to achieve drug targeting.
AB - Even at the early stages of drug discovery and structure-based drug design, the pharmacokinetic, pharmacodynamic and toxicological consequences of drug metabolism cannot be ignored. Drug metabolism is also of interest to medicinal chemists in the design of drugs with controlled, predictable deactivation after achieving the therapeutic objective in prodrug design and in chemical-enzymatic drug targeting. In this review, the authors provide an overview of concepts that can be utilized from drug discovery to pharmaceutical development to overcome problems associated with drug metabolism, or that may be used to take advantage of 'designed-in' metabolic activation to achieve drug targeting.
UR - http://www.scopus.com/inward/record.url?scp=0033231328&partnerID=8YFLogxK
U2 - 10.1016/S1461-5347(99)00208-4
DO - 10.1016/S1461-5347(99)00208-4
M3 - Review article
AN - SCOPUS:0033231328
SN - 1461-5347
VL - 2
SP - 457
EP - 462
JO - Pharmaceutical Science and Technology Today
JF - Pharmaceutical Science and Technology Today
IS - 11
ER -